245 related articles for article (PubMed ID: 30771277)
1. Association Between Activation of the Programmed Cell Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Pathway and Pain in Patients with Cancer.
Zhang J; Zhang H; Luo Y
Med Sci Monit; 2019 Feb; 25():1275-1282. PubMed ID: 30771277
[TBL] [Abstract][Full Text] [Related]
2. [Expression of soluble programmed death-1, soluble programmed death ligand 1 proteins and immune status in patients with oral lichen planus].
Luo L; Shu M; Li S; Cai Y
Zhonghua Kou Qiang Yi Xue Za Zhi; 2015 Oct; 50(10):585-9. PubMed ID: 26757624
[TBL] [Abstract][Full Text] [Related]
3. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.
Chang B; Huang T; Wei H; Shen L; Zhu D; He W; Chen Q; Zhang H; Li Y; Huang R; Li W; Wu P
Cancer Immunol Immunother; 2019 Mar; 68(3):353-363. PubMed ID: 30506460
[TBL] [Abstract][Full Text] [Related]
4. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
[TBL] [Abstract][Full Text] [Related]
5. [Programmed cell death protein 1 and its ligands regulate immune balance in allergic rhinitis].
Wen SL; Li F; Zhao F; Zuo JJ; Deng YQ; Zhang W; Tao ZZ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Apr; 55(4):384-390. PubMed ID: 32306637
[No Abstract] [Full Text] [Related]
6. Influence of total glucosides of paeony on PD-1/PD-L1 expression in primary Sjögren's syndrome.
Chen Y; Wang Y; Xu L; Zhu W; Xu C; Xu M; Guo L; Hu W; Xu D; Jing R; Zhu Y; He J; Xu B
Int J Rheum Dis; 2019 Feb; 22(2):200-206. PubMed ID: 30338648
[TBL] [Abstract][Full Text] [Related]
7. [The content of the soluble forms PD-1 and PD-L1 in blood serum of patients with gastric cancer and their relationship with clinical and morphological characteristics of the disease.].
Gershtein ES; Ognerubov NA; Chang VL; Delektorskaya VV; Korotkova EA; Sokolov NY; Polikarpova SB; Stilidi IS; Kushlinskii NE
Klin Lab Diagn; 2020; 65(6):347-352. PubMed ID: 32459892
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Tominaga T; Akiyoshi T; Yamamoto N; Taguchi S; Mori S; Nagasaki T; Fukunaga Y; Ueno M
PLoS One; 2019; 14(2):e0212978. PubMed ID: 30807610
[TBL] [Abstract][Full Text] [Related]
9. Study on the Expression Levels and Clinical Significance of PD-1 and PD-L1 in Plasma of NSCLC Patients.
He J; Pan Y; Guo Y; Li B; Tang Y
J Immunother; 2020 Jun; 43(5):156-164. PubMed ID: 32168233
[TBL] [Abstract][Full Text] [Related]
10. [Soluble programmed death-1 and soluble programmed death ligand 1 protein expression and immune status in patients with recurrent aphthous ulcer].
Nan J; Liang L; Li L; Xiaoqin S; Xing J; Yang C
Hua Xi Kou Qiang Yi Xue Za Zhi; 2017 Jun; 35(3):286-290. PubMed ID: 28675014
[TBL] [Abstract][Full Text] [Related]
11. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
[TBL] [Abstract][Full Text] [Related]
12. Percentages of PD-1
Wang Y; Pang N; Wang X; Liu Y; Wang X; Wang L; Sun M; Yasen H; Zhao F; Fan W; Guo X; Ding J
Hum Vaccin Immunother; 2018 Apr; 14(4):832-838. PubMed ID: 29333980
[TBL] [Abstract][Full Text] [Related]
13. Contribution of Soluble Forms of Programmed Death 1 and Programmed Death Ligand 2 to Disease Severity and Progression in Systemic Sclerosis.
Fukasawa T; Yoshizaki A; Ebata S; Nakamura K; Saigusa R; Miura S; Yamashita T; Hirabayashi M; Ichimura Y; Taniguchi T; Asano Y; Shimizu H; Kazoe Y; Mawatari K; Kitamori T; Sato S
Arthritis Rheumatol; 2017 Sep; 69(9):1879-1890. PubMed ID: 28556548
[TBL] [Abstract][Full Text] [Related]
14. Elevated Soluble PD-L1 in Pregnant Women's Serum Suppresses the Immune Reaction.
Okuyama M; Mezawa H; Kawai T; Urashima M
Front Immunol; 2019; 10():86. PubMed ID: 30833943
[No Abstract] [Full Text] [Related]
15. [Effects of soluble programmed death ligand 1 on regulating the proliferation of T lymphocytes and its mechanism].
Zhao J; Pan X; Xing Y; Lu M; Chen Y; Shi M
Zhonghua Yi Xue Za Zhi; 2015 Feb; 95(6):449-52. PubMed ID: 25916783
[TBL] [Abstract][Full Text] [Related]
16. Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer.
Takeuchi M; Doi T; Obayashi K; Hirai A; Yoneda K; Tanaka F; Iwai Y
Immunol Lett; 2018 Apr; 196():155-160. PubMed ID: 29366663
[TBL] [Abstract][Full Text] [Related]
17. Unbalanced expression of membrane-bound and soluble programmed cell death 1 and programmed cell death ligand 1 in systemic juvenile idiopathic arthritis.
Cai L; Zhang C; Wu J; Zhou W; Chen T
Clin Immunol; 2021 Aug; 229():108800. PubMed ID: 34289424
[TBL] [Abstract][Full Text] [Related]
18. Smoking Is Associated With Low Levels of Soluble PD-L1 in Rheumatoid Arthritis.
Wasén C; Erlandsson MC; Bossios A; Ekerljung L; Malmhäll C; Töyrä Silfverswärd S; Pullerits R; Lundbäck B; Bokarewa MI
Front Immunol; 2018; 9():1677. PubMed ID: 30140263
[TBL] [Abstract][Full Text] [Related]
19. The role of PD-1/PD-Ls in the pathogenesis of IgG4-related disease.
Zhang X; Lu H; Peng L; Zhou J; Wang M; Li J; Liu Z; Zhang W; Zhao Y; Zeng X; Lu L
Rheumatology (Oxford); 2022 Feb; 61(2):815-825. PubMed ID: 33930105
[TBL] [Abstract][Full Text] [Related]
20. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.
Okuma Y; Hosomi Y; Nakahara Y; Watanabe K; Sagawa Y; Homma S
Lung Cancer; 2017 Feb; 104():1-6. PubMed ID: 28212990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
